Loading
Biomarkers / Alzheimer Disease / Alzheimer’s Disease · unknown
Annals of Medicine · May 20, 2026
A consensus or society position rather than new primary data.
The ADC guideline working group proposes a three-dimensional diagnostic framework and sequential therapy concept for Alzheimer's disease, integrating clinical criteria, biomarkers, syndrome staging, and TCM pattern phenotyping. This represents an expert consensus paradigm requiring future cohort validation rather than evidence from completed trials.
unknown. Patients with Alzheimer's disease across all stages. China.
Diagnostic framework combines core clinical criteria with early-changing biomarkers, syndrome staging and TCM-based pattern phenotyping Sequential therapy uses stage-adaptive treatment adjusted according to disease progression with multi-target combination therapy Biological biomarkers of AD present at all stages but may be unrelated to clinical severity
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This paradigm offers a structured whole-process approach to AD management integrating Western and traditional Chinese medicine perspectives, though its diagnostic performance and clinical benefits remain unvalidated. Clinicians should await cohort-based validation studies before implementation.
Expert working group consensus proposing a diagnostic and therapeutic paradigm without primary data or validation studies.
As stated by the source record.
This paradigm offers a structured whole-process approach to AD management integrating Western and traditional Chinese medicine perspectives, though its diagnostic performance and clinical benefits remain unvalidated. Clinicians should await cohort-based validation studies before implementation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Introduction. The clinical management of Alzheimer's disease (AD) is still constrained by the fact that its incompletely understood pathogenesis, difficulty in early diagnosis and the limited long-term treatment benefits so far. This article summarizes a regional perspective on the diagnosis and treatment of AD from the Alzheimer's Disease Chinese (ADC) guideline working group, aiming to improve the whole-process management of AD.Discussion. The article presents a comprehensive overview of a proposed diagnostic and therapeutic paradigm for AD, consisting of a three-dimensional diagnostic framework and a sequential therapy concept. Crucially, while biological biomarkers of AD are present at all stages, they may be unrelated to clinical severity. To address this, the diagnostic framework combines core clinical criteria with early-changing biomarkers, syndrome staging and traditional Chinese medicine (TCM)-based pattern phenotyping. This integrated, simplified and practical approach enhances diagnostic certainty and its correlation with clinical severity. This sequential therapy is a stage-adaptive treatment plan adjusted according to the disease progression, utilizing a dynamic, multi-target combination therapy. Unlike the existing unchanging single-target therapies, this approach provides specific mechanistic interventions tailored to each stage to prolong efficacy and delay disease progression.Conclusions. This paradigm provides a whole-process, stage-oriented approach to AD diagnosis and management that may improve translational relevance, clinical applicability and continuity of care in real-world settings. Future cohort-based validation studies are needed to confirm its diagnostic performance and clinical benefits, and to refine its implementation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.